Novartis KRW 2.8 billionㆍAstraZeneca KRW 2.5 billion
[Newsmp] Multinational pharmaceutical companies’ subsidiaries in Korea are tightly cracking down on the amount of donations in the COVID-19 situation.
Following 2020, the first year of COVID-19, the third and fourth pandemics continued throughout the last year, and they further reduced donations.
Newsmp tallied the audit reports of multinational pharmaceutical companies whose closing accounts are between September and December and found that the donation amounts of the 35 companies decreased by about KRW 1 billion or 7.4% from KRW 13.3 billion in 2020 to KRW 12.3 billion last year.
Earlier, their donations exceeded KRW 15 billion in 2019, but it dropped by nearly KRW 2 billion in 2020, the first year of COVID-19.
While the donations significantly decreased for the second year in a row, 18 out of 28 companies (based on the company that aggregated the donation amounts in the audit report) that reduced their donations were twice as many as the 9 companies that increased their donations.
In particular, AbbVie Korea’s donations decreased by more than KRW 1 billion from KRW 1.2786 billion in 2020 to KRW 238.59 million last year.
Korea Otsuka Pharmaceuticals’ donations were also reduced by more than KRW 500 million from KRW 800 million to KRW 300 million, Pfizer Pharmaceutical Korea KRW 400 million from about KRW 700 million to KRW 370 million, Novartis Korea KRW 260 million from KRW 3.9 billion to 2.83 billion and MSD Korea KRW 200 million.
The amount of donations from AstraZeneca Korea and Boehringer Ingelheim Korea has also been reduced by more than KRW 100 million, while donations from Bayer Korea, Sanofi-Aventis, GSK, BMS Korea, Guerbet Korea, Mundipharma Korea, Janssen Vaccine, Ferring Korea, Amgen, Sanofi Pasteur, and Novo Nordisk have also dropped from 2020.
On the other hand, during the same period, donations from Kyowa Kirin Korea and Janssen Korea increased by nearly KRW 700 million, and Roche by about KRW 500 million.
Celgene Korea’s donations have also expanded by more than KRW 200 million, while Lilly Korea, Korea UCB, GSK Consumer Healthcare Korea, Lundbeck Korea, and Viatris Korea also grew their donations from 2020.
Novartis Korea had the largest annual donation of KRW 2.2848 billion last year, followed by AstraZeneca Korea with KRW 2.4923 billion.
In addition, five companies surpassed KRW 1 billion, including Kyowa Kirin Korea with KRW 1.891 billion, Roche Korea with KRW 1.484 billion, and Janssen Korea with KRW 1.186 billion, followed by Pfizer Pharmaceutical Korea with KRW 370 million, Korea Otsuka Pharmaceuticals with KRW 310 million, Celgene Korea with KRW 290 million, Sanofi-Aventis with KRW 260 million, BMS Korea and AbbVie Korea with KRW 240 million, GSK and Korea UCB with 140 million, and Bayer Korea with KRW 120 million.
